Teva Advances TEV-'408 Anti-IL-15 Antibody Into Phase 2b Vitiligo Study After Phase 1b Data

Quarterly subcutaneous dosing is now a design specification, not a convenience feature, and Teva's decision to move TEV-'408 into a Phase 2b vitiligo study in Q4 2026 puts that specification on a development timeline that formulation and fill-finish teams will need to plan against. The investigational anti-interleukin-15 monoclonal antibody is engineered with a prolonged half-life targeting a Q12W subcutaneous administration schedule, a dosing interval that carries distinct implications for device selection, primary container closure, and subcutaneous formulation stability packages.

Phase 1b data from the ongoing open-label study in adults with active or stable non-segmental vitiligo (NSV) supported the advancement decision. At week 24, nearly 75% of evaluable patients reported improvement in facial vitiligo, with half characterising improvement as "much" or "very much." On the validated F-VASI scale, 42% achieved F-VASI50 and 21% achieved F-VASI75. Total body response was more modest: 55% reported improvement, with 7% reaching T-VASI50. TEV-'408 was well-tolerated with no safety signals observed to date. The enrolled population skewed toward moderate-to-severe disease, with 66% of participants presenting with vitiligo affecting more than 10% of body surface area at baseline.

For development operations leads, the Q12W design compresses the number of administration events across a trial but raises the concentration and volume requirements per injection that subcutaneous formulation scientists must resolve early. Autoinjector or prefilled syringe platform selection, viscosity management, and extractables and leachables profiling under ICH Q1 stability conditions will each need to be locked before Phase 2b manufacturing runs begin. Any comparability gaps introduced during scale-up will require documented bridging under 21 CFR Part 211 and the relevant ICH Q5E framework if the molecule's half-life characteristics are sensitive to process changes.

The IL-15 pathway is gaining traction across multiple autoimmune indications, and Teva's Phase 2b entry adds a data-generating programme that will inform both the regulatory path and the competitive formulation landscape for this target class. The Phase 1b monitoring window extends through week 80, meaning longer-term safety and durability data will continue to accumulate in parallel with Phase 2b design and site activation work.

The Phase 2b study initiation, currently targeted for Q4 2026, will serve as the first measurable checkpoint against which Teva's formulation readiness and manufacturing scale-up timelines can be assessed.

Source: Teva Pharmaceutical Industries Ltd. via GlobeNewswire, 7 July 2026. Investor call and live webcast held 7 July 2026 at 8:00 a.m. ET.